Le Lézard
Classified in: Health, Business
Subjects: LIC, MAT

Alternate Health Obtains California Cannabis Distribution, Manufacturing and Cultivation Licenses Through Acquisition


TORONTO, Oct. 17, 2018 /PRNewswire/ - Alternate Health Corp., ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international leader in technology solutions for the regulated cannabis industry, announced today that the Company signed an arms length  agreement on October 16, 2018, to acquire 100% of Four Twenty Inc., receiving coveted cannabis distribution, manufacturing, processing and cultivation permits as part of the agreement. Four Twenty Inc. also holds a five-year lease with an extension and purchase option on a 14,800 square foot, licensed facility in Humboldt County, California.

Alternate Health Corp. (CNW Group/Alternate Health Corp.)

"With this acquisition, Alternate Health has the potential to take a leadership position in California's cannabis industry," says Dr. Murphy, Chairman and CEO of Alternate Health. "Based in the heart of Humboldt County, Four Twenty Inc. is strategically located giving Alternate Health the capacity to capture a dominant portion of the distribution market in one of the world's most famous and well-respected cultivation areas."

Four Twenty Inc. was established in 2015 by George Mull, a distinguished attorney and one of California's foremost experts in the legal cannabis industry. Originally founded to provide consulting and legal advice for cannabis licensing and operations, Four Twenty Inc. has developed strong relationships with an extensive network of premiere cultivators throughout Humboldt County. These relationships form a key competitive advantage as Alternate Health and Four Twenty Inc. expand into cannabis distribution and product development.

Highlights of the Four Twenty Acquisition:

Peter Fimrite: "Allure of Legal Weed is fueling a land rush in Emerald Triangle." San Francisco Chronicle, May 27, 2016

Alternate Health plans on operating the Four Twenty Inc. subsidiary primarily as a distribution and packaging consulting company. Four Twenty Inc. will continue its management consulting and compliance advice activities with cultivators, but with a focus on incentivizing exclusive distribution deals. The manufacturing, processing, distribution and cultivation permits will be transferred to subsidiaries of Alternate Health. Alternate Health will earn revenues from associated distribution, processing, packaging and transport fees.

Alternate Health intends to establish retail distribution channels to dispensary partners in Los Angeles County. According U.S. Census Bureau data, the combined Los Angeles ? Orange County metropolitan area has economy of over $1 trillion. Alternate Health recognizes the tremendous potential the Humboldt brand has among Los Angeles customers.

"Now is the perfect time to expand into California's cannabis distribution market," says Dr. Murphy. "The state's cannabis regulations are just beginning to come into effect and, with our new permits and facility, we are well positioned to capture cannabis revenues as California phases out grey market sales."

About Humboldt Ave. Cannabis

Alternate Health. is focused on growing the Humboldt Ave. brand, distributing high quality cannabis from Humboldt to dispensary partners in the Greater Los Angeles area. With hundreds of cultivators in Humboldt County, Four Twenty Inc. has provided Alternate Health with the network to supply high quality cannabis to the world's most valuable cannabis market.

In an industry driven by quality, Humboldt Ave Cannabis enjoys the following benefits:

For more information on the Humboldt Ave. brand, visit www.HumboldtAve.com.

Terms of the Agreement

As consideration for the acquisition, Four Twenty Inc. founder, George Mull, will receive 1,000,000 warrants for common stock in Alternate Health Corp. The warrants have a five-year term with an exercise price per share of CDN$ 0.57. In addition, the Company is entering a management contract with George Mull or an entity controlled by George for a fee equal to 20% of net income, defined as revenue less all expenses from certain operations of Alternate Health to be mutually agreed.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects, anticipated lab sample increases and potential revenues, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

SOURCE Alternate Health Corp.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: